Document:

Execution
Version

 

FORM
OF

 

INDIVIDUAL
EMPLOYMENT AGREEMENT ENTERED INTO, BY AND BETWEEN, ON THE ONE PART VITEL LABORATORIOS, S.A DE C.V. HEREINAFTER REFERRED
TO AS “THE COMPANY”, REPRESENTED BY MANUEL COSME ODABACHIAN, AND ON THE OTHER PART, [__], IN HIS OWN RIGHT,
HEREINAFTER REFERRED TO AS THE “EMPLOYEE”, ON HIS OWN RIGHT, WITH THE APPEARANCE OF ONCBIOMUNE PHARAMCEUTICALS,
INC., HEREINAFTER REFERRED TO AS “GUARANTOR”, REPERESENTED BY ANDREW ALBERT KUCHARCHUK, UNDER THE FOLLOWING RECITALS
AND CLAUSES:

 

R
E C I T A LS

 

	I.	The
                                         Company represents that it:

 

	 	a)	Is
    a company duly organized in accordance with the laws of the United States of Mexico.
	 	 	 
	 	b)	It
    is domiciled at [__], and has the following RFC: [__].
	 	 	 
	 	c)	Desires
    to retain the services of an individual with the experience, capacity and ability necessary to hold the position of Chief
    Operations Officer, which is a position of “trust” with the Company.

 

	II.	The
                                         Employee represents that:

 

	 	a)	His
    name is as hereinabove set forth, that he is a male of Mexican nationality, born in Mexico City, that he is born on [__],
    that he is married, domiciled at [__], has the following RFC: [__], and the following CURP: [__].
	 	 	 
	 	b)	He
    is familiar with the work that he is to perform for the Company and has the necessary knowledge and experience to carry out
    the duties assigned to him as the [__], under the terms of this Agreement.
	 	 	 
	 	c)	 Conflict
    of Interests. Employee hereby agrees that all of his decisions and actions with respect of the Company shall be made primarily
    for the benefit of the Company, and not for Employee’s individual benefit.

 

To
avoid any conflict of interest, Employee agrees:

 

	 	1.	To
    notify the Company in writing of any corporate or business ties, employment or other circumstance which could originate a
    conflict of interest, except as it relates to the Excluded Business;
	 	 	 
	 	2.	To
    reject any payment or consideration from any third party, in any form, that may affect Employee’s ability to make independent
    decisions related to the Company;

 

     

    	 	 	2

    

 

	 	3.	Not
    to make or offer any gifts of any kind to third parties, in exchange for services from the Company, except for customary gifts;
	 	 	 
	 	4.	Not
    to perform any activities for personal gain or in favor of third parties which could imply a competing activity except as
    provided for in Clause Seventeenth; and
	 	 	 
	 	5.	Conduct
    Employee’s duties ethically, in compliance with laws and pursuant to the business judgment rule, and in any case in
    such a way as not to adversely affect the reputation of the Company.

 

	III.	The
                                         Guarantor represents that:

 

	 	a)	It
    is a legal entity duly organized and legally existing in accordance with the laws of the State of Nevada, United States of
    America
	 	 	 
	 	b)	Andrew
    Albert Kucharchuk has the necessary authorities to represent it and bind it for the purposes set forth in Clause Sixteenth
    of this Agreement.

 

In
consideration of the foregoing, the Parties agree to the following:

 

C
L A U S E S

 

FIRST.
- Indefinite Term Agreement. The term of this Agreement is indefinite (the “Term”) and shall begin having
effects on the date hereof (the “Effective Date”).

 

SECOND.
- Position and Activities. The Employee agrees to carry out his personal services for the Company as Chief Operations
Officer as set forth below, together with such other duties as may be reasonably required from time to time by the Board of Directors
of the Company. The Employee and Manuel Cosme Odabachian shall be the employees and officers of the Company with the highest level
of authority thereat, being subordinated only and exclusively to the Board of Directors of the Company (and the Board of Directors
of Guarantor in the case of deadlock).

 

The
activities that the Employee has to execute while rendering his services consist of Chief Operations Officer, including without
limitation, supervising, managing, planning, directing and organizing the activities of the Company and its subsidiaries. The
Employee shall be one of the two most senior executive officers of the Company, and all other employees of the Company shall report
directly or indirectly to him, except for Manuel Cosme Odabachian, who will hold a position of similar ranking to the Employee.

 

The
Employee will perform his services at the domicile of the Company located at Mexico City, Mexico except for certain travel as
reasonably required in the performance of the Employee’s duties under this Agreement.

 

THIRD.
- Work Shift. The Employee shall render his services to the Company during the necessary hours to meet the high level
responsibilities assigned to him as per this Agreement, and within a schedule during normal business hours to be self-determined
by him at his reasonable discretion but which may not exceed from 40 (forty) hours per week, from Monday to Friday. Employee acknowledges
that as part of his responsibilities under this Agreement, some traveling may be required outside of these prescribed business
hours.

 

     

    	 	 	3

    

 

FOURTH.
– Salary. As remuneration for his services, the
Employee will receive a monthly salary in the amount of US$15,625.00 (Fifteen Thousand Six Hundred and Twenty Five 00/100 Dollars),
less applicable payroll deductions.

 

The
Monthly Salary will be paid to the Employee in arrears, half of it every fifteen days. The Parties agree that the salary already
includes the payment of the days of rest and legal holidays. The salary shall be paid to Employee in Mexican Pesos, in accordance
with the exchange rate published in the Mexican Federal Official Gazette, on the business
day prior to the payment date. 

 

FIFTH.
– Extralegal Benefits. The Employee shall enjoy the extralegal benefits
described in Exhibit “A” hereto.

 

SIXTH.
– Rest for Obligatory Legal Holidays.
The Company shall provide the Employee with obligatory holidays, in accordance with the
provisions of the Federal Labor Law.

 

SEVENTH.
– Vacations and Vacation Premium. The
Employee shall enjoy 15 (fifteen) days of vacation per year.

The
Company shall pay the Employee a vacation premium equivalent to 25% (twenty-five percent) of the vacation days corresponding to
him, in accordance to article 80 of the Federal Labor Law (the “Vacation Premium”). 

 

EIGHTH.
– Year End Bonus. The Parties agree that the Company will pay to the Employee an annual Year End Bonus equal
to 15 (fifteen) days of salary, no later than December 20 of each year (the “Year End Bonus”). 

 

NINTH.
– Reimbursement of expenses. Should the Employee in meeting his obligations, need to travel to other places within
or outside the Mexican Republic, and to incur in transportation, lodging and meal expenses, he shall incur them on them on the
basis of reasonable expenditures in accordance with the policies that the Company has in place at that time. 

 

TENTH.
– Medical Examinations. The Employee agrees to submit himself to periodical medical examination whenever the
Company requires so, in accordance with the provisions of Section X of the Article 134 of the Federal Labor Law, in the understanding
that the physician who practices such will be designated and paid by the Company. 

 

ELEVENTH.
– Social Security. The Employee shall be enrolled with the Mexican Social Security Institute in order to receive
Mexican Social Security medical benefits. The Company will be authorized to make the necessary discounts from the Employee’s
salary in order to cover before the Mexican Institute of Social Security the corresponding fees. Both Parties agree to comply
with all matters relative to the Social Security Law and its Regulations. 

 

TWELFTH.
– Training. The Employee will be trained by the Company in accordance with the planning and training programs
established by the Company.

 

     

    	 	 	4

    

 

THIRTEENTH.
– Member on Third Party’s Board of Directors. The employee shall be able to be appointed as a member of
the Board of Directors and/or Board of Managers of any company that does not directly compete with the Company. 

 

FOURTEENTH.
– Employee’s Seniority. The Company recognizes to the Employee a seniority as of February
18, 2016, which shall serve exclusively as a reference to determine the rights and obligations that derive from this employment
relationship, and in particular to compute the payment set forth in the Clause Fifteenth below.

 

FIFTEENTH.
– Conventional Payment for termination of the Agreement.

 

If
within three years of the Effective Date (a) Employee’s employment with the Company is terminated by the Company without
Cause, or (b) Employee terminates his employment with the Company or resigns for Good Reason, Employee will be paid by the Company
either (i) the equivalent amount of the corresponding severance payment set forth in the Federal Labor Law for an unjustified
dismissal , OR if greater (ii) the equivalent amount of up to three years’ gross salary, depending on the date of termination
(the “Severance Payment”). In case of clause (ii), the Severance Payment shall be reduced by an amount equal to the
product of (i) a fraction the numerator of which is the number of completed months elapsed after the Effective Date to the date
of termination, and the denominator of which is thirty-six (36) (the “Remaining Term”) and such fraction shall be
multiplied by (ii) the Severance Payment. The Severance Payment shall be paid in equal monthly installments over the Remaining
Term so long as Employee is in compliance with the Non-Compete provisions provided for in
Clause SEVENTEENTH below. In addition, Employee shall be obligated to
sign a release agreement in such form and content as reasonably approved by the Company prior to payment of the Severance Payment.

 

Besides
the meaning attributed to it in the Federal Labor Law, “Cause” will also mean the:

 

	1.	Employee’s
    conviction of, or plea of “no contest” to, a felony or its equivalent under Mexican law; 
	 	 
	2.	Employee’s
    willfully engaging in an act or series of acts of gross misconduct that result in demonstrable and material injury to the
    Company or the Guarantor; or 
	 	 
	3.	Employee’s
    material breach of any provision of this Agreement, which breach has not been cured in all material respects within twenty
    (20) days after the Company gives notice thereof to Employee.

 

“Good
Reason” means the occurrence of any of the following events without the Employee’s prior written consent, unless within
30 days after the Employee gives written notice of such event, the Company cures any such event:

 

	1.	the
    Company’s material breach of this Agreement;
	 	 
	2.	the
    Company’s appointment/hiring of any employee or officer that is not subordinated to the Employee or Manuel Cosme Odabachian,
    so long as such person is employed by the Company, or any of its affiliates or subsidiaries;

 

     

    	 	 	5

    

 

	3.	a
    material diminution in the Employee’s responsibilities or authorities, or a material adverse change in his position
    or title;
	 	 
	4.	a
    material reduction in the Employee’s Salary or benefits, including his Performance Bonus; or
	 	 
	5.	relocation
    of the Employee’s principal place of work by more than 75 kilometers without the Employee’s prior written consent.

 

Any
occurrence of a Good Reason event shall be deemed to be waived by the Employee unless he gives the Company written notice of such
event within 90 days after it occurs and he terminates his employment hereunder within one year after such event occurs.

 

SIXTEENTH.-
Guaranty. Guarantor hereby guarantees the correct and complete compliance of the obligations set on the Company as per
Clause Fifteenth of this Agreement, and therefore jointly with the Company, obligates to pay to the Employee exclusively the Conventional
Payment set forth in it, should the events described therein come to materialize.

 

This
does not create an employment relationship between the Employee and the Guarantor.

 

SEVENTEENTH.-Non-Compete
and Non-Solicitation. 

 

(a)       For
a period of five (5) years from the Effective Date, the Employee shall not, nor shall he permit, cause or encourage anyone to,
engage directly or indirectly, as an owner, employee, consultant, contractor or otherwise, in any business or enterprise that
is engaged in the development, commercialization, sales of the OBMP Products, the OBMP Pipeline Products or the Vitel Products
(collectively, the “Restricted Business”) anywhere in the world as well as clinical development and marketing of therapeutic
candidates similar to products that are part of the Restricted Business anywhere in the world except for those activities listed
on Exhibit “B” (the “Excluded Businesses”); provided, that no owner of less than 5% of the
outstanding stock of any publicly-traded corporation will be deemed to be so engaged solely by reason thereof in the Business.
For a period of five (5) years from and after the date of this Agreement, the Employee shall not, and shall not permit, cause
or encourage anyone to, solicit, recruit, offer employment, hire, employ, engage as a consultant, lure or entice away, or in any
other manner persuade or attempt to persuade, any Person who is an employee of any of Guarantor or the Company to leave the employ
of Guarantor or the Company. If the final judgment of a court of competent jurisdiction declares that any term or provision of
this Clause SEVENTEENTH
is invalid or unenforceable, the parties hereto agree that the reduction in the scope, duration,
or area of the term or provision, or the deletion of specific words or phrases, or the replacement of any invalid or unenforceable
term or provision shall be carried out so as to include a term or provision that is valid and enforceable and that comes closest
to expressing the intention of the invalid or unenforceable term or provision, and this Agreement will be enforceable as so modified
after the expiration of the time within which the judgment may be appealed.

 

     

    	 	 	6

    

 

(b)       Notwithstanding
anything to the contrary in paragraph (a) above, in no event shall the Employee be prohibited from engaging in any business under
the following conditions:

 

Employee
shall promptly notify the Company and Guarantor in writing of any business opportunities in ROW with regard to any expansion of
any business activity currently conducted by the Employee beyond the Excluded Contracts so long as such business (i) does not
interfere with Employee’s duties under this Agreement and (ii) does not compete with any of the products that are part of
the Restricted Business anywhere in the world (the “ROW Opportunity”). The Company or Guarantor who is presented with
an ROW Opportunity, shall have a period of thirty (30) days in which to decide to participate. In the event the parties to the
ROW Opportunity are unable to reach an agreement to consummate the transaction contemplated by the ROW Opportunity within thirty
(30) days, the Employee shall be free to pursue the ROW Opportunity without the Company or the Guarantor.

 

Defined
terms in this Clause shall have the meaning attributed to them in Exhibit “B” hereto. 

 

EIGHTEENTH.-
Applicable law and jurisdiction. The Parties agree that for any matter not covered by this Agreement, the provisions
of the Federal Labor Law shall apply, and in case of any conflict or controversy arising as a consequence of the execution, interpretation
or enforcement of this Agreement, they submit to the jurisdiction of the corresponding Labor Conciliation and Arbitration Board

 

March
10, 2017.

 

	THE
    EMPLOYEE/ EL EMPLEADO	 	THE
    COMPANY/LA COMPAÑÍA
	 	 	 
	 	 	 
	Carlos
    Fernando Alamán Volnie	 	Manuel
    Cosme Odabachian

 

GUARANTOR

 

________________________________

 

Oncbiomune
Pharmaceuticals, Inc.

Attorney-in-fact

 

     

    	 	 	7

    

 

EXHIBIT
“A”

 

EXTRALEGAL
BENEFITS OF EMPLOYEE

 

The
Employee shall enjoy the following benefits in additions to the ones set forth in this Agreement:

 

	●	Car
    Allowance. –Throughout the first 3 years of this Agreement, the Company will pay the Employee the gross amount of
    US$500.00 (Five hundred 00/100 US Dollars) per month, as a car allowance for the Employee. 
	 	 
	 	The
    car allowance will be paid to the Employee in
    Mexican Pesos, taking into accordance the US Dollar exchange rate (USD) published in
    the Mexican Official Gazette, on the prior business day to the payment date. 
	 	 
	●	Health
    Insurance Allowance. –. On a monthly basis, the Company will reimburse Employee or pay the cost of Employee’s
    major medical insurance policy covering Employee and his family selected by Employee up to an annual amount of insurance premiums
    of USD$5,000.00 (the “Health Insurance Allowance”), in the understanding that any amount in excess of such Health
    Insurance Allowance will not be covered by the Company. 
	 	 
	 	The
    Health Insurance allowance will be paid to the Employee in Mexican Pesos, taking into accordance the US Dollar exchange rate
    (USD) published in the Mexican Official Gazette, on the prior business day to the payment date
	 	 
	●	Performance
    Bonus. Every year the Employee
    will be given an annual performance objectives for the Company, pursuant to the payment of a bonus (the “Bonus”);
    the bonus target, will be an amount equal to fifty percent (50%) of his Salary (the “Bonus Target”). The performance
    objectives will be established by the Guarantor’s Board of Directors and communicated to the Employee in writing as
    soon as practicable after commencement of every calendar year. The Bonus may be greater or less than the Target Bonus (ranging
    from a threshold Bonus to a maximum Bonus), based on the level of achievement of the applicable performance objectives.

 

March
10, 2017.

 

	THE
    EMPLOYEE/ EL EMPLEADO	 	THE
    COMPANY/LA COMPAÑÍA
	 	 	 
	Carlos
    Fernando Alamán Volnie	 	Manuel
    Cosme Odabachian

 

GUARANTOR

________________________________

Oncbiomune
Pharmaceuticals, Inc.

Attorney-in-fact

 

     

    	 	 	8

    

 

EXHIBIT
“B”

 

ACTIVITIES
NOT SUBJECT TO NON-COMPETE

 

The
following business activities shall be deemed Excluded Business as provided for in this Agreement so long as such business activity
(i) is currently conducted by the Employee pursuant to the terms of any contract or agreement (the “Excluded Contracts”)
as in effect as of the Effective Date and for so long as such contract or agreement is in effect, without any amendment to or
renewal of such contract or agreement after the Effective Date; (ii) does not interfere with Employee’s duties under this
Agreement and (iii) does not compete with any of the products that are part of the Restricted Business anywhere in the world (collectively,
the “Excluded Business”):

 

	-	Clinical
    trials & contract research organization (CRO) services in Mexico.
	 	 
	-	Regulatory
    affairs consulting services and third party lobbying for sanitary registrations in Mexico.
	 	 
	-	Warehousing
    and/or hosting of pharmaceutical, biological, over-the-counter (OTC), supplements, medical devices and other health care products
    in Mexico.
	 	 
	-	Distribution
    of pharmaceutical, biological, OTC, supplements, medical devices and other health care products to the private and/or government
    segment in Mexico.
	 	 
	-	Manufacturing
    and development of branded generics, cosmetic, medical devices and private labels throughout Mexico.
	 	 
	-	Consulting
    services to international and Mexican companies in the healthcare market.
	 	 
	-	Consulting
    for the sale, license, acquisition for Mexican and/or foreign companies in Mexico.

 

Within
20 days from the Effective Date, Employee shall provide the Company with a list of the Current Contracts.

 

     

    	 	 	9

    

 

NEW
DEFINED TERMS

 

“OBMP
Products” shall mean the following:

 

(a)
Proscavax® Prostate Cancer;

 

(b)
OBMP Pipeline; and

 

(c)
OBMP vaccine technology, OBMP cancer technologies for the treatment of prostate, ovarian and various other types of cancer and
any other technology for medical treatment, drug or medical treatment owned by OBMP or by any OBMP related Person or that use
or are based on the technology included in the OBMP IP Rights, the OBMP Licensed IP Rights, the OBMP Owned Rights or the OBMP
Registered IP Rights.

 

“OBMP
Pipeline” shall mean the following:

 

(a)
Ovcavax® Ovarian Cancer;

 

(b)
PA-OBC – Breast Cancer; 

 

(c)
PGT-OBM – Renal Cancer; and

 

(d)
Any other product under development, developed or to be developed by OBMP and/or by Dr. Jonathan F. Head in collaboration, under
contract or under any other type of business relationship with OBMP or with any OBMP related Person.

 

“Vitel
Products” shall mean the following:

 

(a)
Any other product under development, developed or to be developed by Vitel that use or are based on any Vitel IP Rights, Vitel
Licensed IP Rights, the Vitel Owned IP Rights and the Vitel Registered IP Rights, or under contract or under any other type of
business relationship involving a Material Contract, the Vitel IP Rights, the Vitel Licensed IP Rights, the Vitel Owned IP Rights
and the Vitel Registered IP Rights.

 

“ROW”
shall mean all the countries and territories in the world.FORM
OF

 

AMENDMENT
TO EMPLOYMENT AGREEMENT

Andrew
Kucharchuk

 

THIS
AMENDMENT TO EMPLOYMENT AGREEMENT (the “Amendment”) is made effective as of March 10, 2017 by and between OncBioMune
Pharmaceuticals, Inc., a Nevada corporation (the “Company”) and [__] (“Executive”). The Company and Customer
may collectively be referred to as the “Parties”.

 

BACKGROUND

 

A.
The Company and Executive are the parties to that certain Employment Agreement dated as of February 2, 2016 (the “Agreement”);
and

 

B.
The parties desire to amend certain parts of the Agreement as set forth below.

 

NOW,
THEREFORE, in consideration of the execution and delivery of the Agreement and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:

 

1.
Section 2 of the Agreement is hereby amended by deleting the existing Section 2 in its entirety and replacing it with the
following:

 

2.
Term. Subject to the provisions for termination hereinafter provided, the term of this Agreement shall begin on the date
hereof and shall end at 11:59 p.m., local time, on March 9, 2020, provided, however, that the term of this Agreement shall automatically
renew for successive one year terms, unless Executive or the Company gives written notice to the other not less than one hundred
twenty (120) days prior to March 9, 2020 or the expiration of any such one-year term that he or it, as the case may be, is electing
not to so extend the term of this Agreement (the “Employment Period”). Notwithstanding the foregoing, the term
of this Agreement shall end on the date on which Executive’s employment is earlier terminated by him or the Company in accordance
with the provisions of Paragraph 7(a) below.

 

Section
8(a) of the Agreement is hereby amended by deleting the existing Section 8(a) in its entirety and replacing it with the following:

 

8.
Certain Termination Payments.

 

(a)
If Executive’s employment with the Company is terminated by the Company without Cause or by Executive pursuant to Paragraph
7(a)(v), the Company shall (i) continue to pay to Executive the per annum rate of salary then in effect under Paragraph 4(a) and
provide him and his family with the benefits described in Paragraph 4 then in effect (unless the terms of the applicable plans
expressly prohibit the continuation of such benefits after such termination and cannot be amended, with applicability of such
amendment limited to Executive, to provide for such continuation, in which case the Company shall procure and pay for substantially
similar substitute benefits except for any pension or 401(k) Plan benefit) for the balance of the term that would have remained
hereunder had such termination not occurred and (ii) Executive will be entitled to 100% vesting of any unvested portion of any
outstanding equity, or equity-based award granted to Executive by the Company (an “Equity Award”). In addition, Executive
will be entitled to 100% vesting of any Equity Award upon Executive’s death or Disability.

 

    	 	-1-	 

    	 	 	 

    

 

3.
This Amendment shall be deemed part of, but shall take precedence over and supersede any provisions to the contrary contained
in the Agreement. All initial capitalized terms used in this Amendment shall have the same meaning as set forth in the Agreement
unless otherwise provided. Except as specifically modified hereby, all of the provisions of the Agreement which are not in conflict
with the terms of this Amendment shall remain in full force and effect.

 

IN
WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.

 

	OncBioMune
Pharmaceuticals, Inc.

	 	Executive

	 	 	 	 
	By:	 	 	 
	Print
    Name:	 	 	[_]
	Its:	 	 	 

 

    	 	-2-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}]]